The association between Interleukins 6, 8, and 10 levels and response to treatment of the hepatitis C virus with direct-acting antiviral.

The infection caused by the Hepatitis C virus (HCV) is considered a major health problem worldwide, impacting millions of people. In recent years, the treatment options for HCV have significantly advanced, mainly because of the introduction of direct-acting antiviral (DAA) medications. Nevertheless, exploring the host immune response, specifically the involvement of interleukins (ILs), in the context of HCV treatment continues to be an ongoing research topic. This review article seeks to investigate the clinical importance of interleukins 6, 8, and 10 in the therapy of HCV. It has been well-recognized that interleukins are essential agents in the immune response and have vital functions in controlling inflammation, antiviral defense systems, and tissue repair. Interleukins such as IL-6, IL-8, and IL-10 show a substantial role in the development and treatment response of HCV infection. The study analyzes a wide range of research findings to emphasize the potential predictive utility of these interleukins as biomarkers for forecasting treatment response and disease progression. The article explores the various roles of IL-6, IL-8, and IL-10 in the therapy of HCV, including their participation in viral elimination, the advancement of fibrosis, and the regulation of antiviral immune responses. Moreover, it investigates the influence of DAA therapies on the manifestation and fluctuations of these interleukins throughout treatment and post-treatment. Furthermore, recent findings designate that IL-6, IL-8, and IL-10 have the potential to be useful indicators for assessing the effectiveness of treatment, forecasting treatment results, and identifying individuals who may benefit from customized therapeutic strategies.